Anavex Life Sciences Corp (AVXL)

[dennisdave]

I agree with you. I agree that the market expects a P3 if not the market would reflect a x3 higher MC for Anavex. So yes if the EXCELLENCE readout and especially the peer-reviewed medical journal indicates that a Phase 3 trial is likely not needed then that will have a huge impact on Anavexs SP/MC.

In my view, this is not a certain victory even if the data will show efficiency. And this is my opinion but I think/speculate that after the Aducanumab debacle AND because we also have Cassava claiming to have a working AD drug as well it would not surprise me if the FDA would want to be extra super careful not to make any new mistake and NOT give Ananvex or Cassava the benefit of the doubt which would result in Anavex having to start a final confirmatory P3 study